BIO-PATH HOLDINGS, INC. (BPTH): Nasdaq/NYSE listing notice — Bio-Path receives Nasdaq delisting notice for failing $2.5M equity minimum

BIO-PATH HOLDINGS, INC.

Deficiency letter received March 12, 2024 citing non-compliance with Nasdaq Listing Rule 5550(b)(1).
Company has until April 26, 2024 to submit a plan to regain compliance.
If plan accepted, Nasdaq may grant up to 180 days extension to cure deficiency.
Common stock continues trading on Nasdaq Capital Market under symbol BPTH pending review.
Company evaluating options but no assurance of regaining compliance or avoiding delisting.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BIO-PATH HOLDINGS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

March 12, 2024, Bio-Path Holdings, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement of at least $2,500,000 for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock will continue to trade on The Nasdaq C

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-003118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.